` CLLS (Cellectis SA) vs S&P 500 Comparison - Alpha Spread

CLLS
vs
S&P 500

Over the past 12 months, CLLS has underperformed S&P 500, delivering a return of -9% compared to the S&P 500's +16% growth.

Stocks Performance
CLLS vs S&P 500

Loading
CLLS
S&P 500
Add Stock

Performance Gap
CLLS vs S&P 500

Loading
CLLS
S&P 500
Difference
www.alphaspread.com

Performance By Year
CLLS vs S&P 500

Loading
CLLS
S&P 500
Add Stock

Competitors Performance
Cellectis SA vs Peers

S&P 500
CLLS
ABBV
CYTH
AMGN
GILD
Add Stock

Cellectis SA
Glance View

Market Cap
185.2m USD
Industry
Biotechnology

Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. The company is headquartered in Paris, Ile-De-France and currently employs 345 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

CLLS Intrinsic Value
3.88 USD
Undervaluation 52%
Intrinsic Value
Price
Back to Top